文献速递泌尿男性生殖肿瘤

活检格里森评分9-10前列腺癌根治性前列腺切除与放疗比较及死亡风险

Surgery vs Radiotherapy in the Management of Biopsy Gleason Score 9-10 Prostate Cancer and the Risk of Mortality.
PubMed 文献 · JAMA Oncol · 2019-01-01

该队列纳入639例活检格里森评分9-10前列腺癌男性,比较最大雄激素阻断联合根治性前列腺切除(MaxRP)与最大雄激素阻断联合外照射放疗(MaxRT)的死亡风险。中位随访后,MaxRP与MaxRT相比前列腺癌特异性死亡风险(aHR 1.33,95%CI 0.49-3.64,P=0.58)和全因死亡风险(aHR 0.80,95%CI 0.36-1.81,P=0.60)均无显著差异,等效性可信度分别为76.75%和77.97%。作者认为两种治疗可能带来等效的死亡风险。

要点

  • 比较MaxRP(根治性前列腺切除联合盆腔淋巴结清扫,部分辅以放疗/雄激素剥夺)与MaxRT(外照射放疗联合近距离放疗和雄激素剥夺)的死亡风险。
  • MaxRP与MaxRT相比,前列腺癌特异性死亡风险aHR 1.33(95%CI 0.49-3.64,P=0.58),无显著差异。
  • MaxRP与MaxRT相比,全因死亡风险aHR 0.80(95%CI 0.36-1.81,P=0.60),无显著差异。

核心结论

  • 作者认为,对于活检格里森评分9-10的前列腺癌男性,MaxRP或MaxRT治疗可能带来等效的前列腺癌特异性死亡风险和全因死亡风险。

研究设计与样本

  • 研究为队列研究,纳入639例临床T1-4,N0M0活检格里森评分9-10前列腺癌男性。
  • 1992年2月6日至2013年4月26日,80例在芝加哥前列腺癌中心连续接受MaxRT治疗,559例在Martini-Klinik前列腺癌中心连续接受根治性前列腺切除加盆腔淋巴结清扫。
  • 随访自前列腺外照射放疗或根治性前列腺切除之日起,至2017年10月27日结束。
  • 559例接受根治性前列腺切除加盆腔淋巴结清扫者中,88例(15.7%)接受辅助外照射放疗,49例(8.8%)接受雄激素剥夺治疗,50例(8.9%)两者均接受。

主要发现

  • 队列平均(标准差)年龄为65.83(6.52)岁。
  • 80例MaxRT治疗者中位随访5.51年(四分位距2.19-6.95年),559例含根治性前列腺切除治疗者中位随访4.78年(四分位距4.01-6.05年)。
  • 161例死亡,其中106例(65.8%)死于前列腺癌。
  • MaxRP与MaxRT相比,前列腺癌特异性死亡风险校正风险比1.33(95%CI 0.49-3.64,P=0.58),无显著差异。
  • MaxRP与MaxRT相比,全因死亡风险校正风险比0.80(95%CI 0.36-1.81,P=0.60),无显著差异。

临床怎么用

  • 作者认为,对于活检格里森评分9-10的前列腺癌男性,MaxRP或MaxRT治疗可能带来等效的前列腺癌特异性死亡风险和全因死亡风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: It is unknown how treatment with radical prostatectomy (RP) and adjuvant external beam radiotherapy (EBRT), androgen deprivation therapy (ADT), or both (termed MaxRP) compares with treatment with EBRT, brachytherapy, and ADT (termed MaxRT). OBJECTIVE: To investigate whether treatment of Gleason score 9-10 prostate cancer with MaxRP vs MaxRT was associated with prostate cancer-specific mortality (PCSM) and all-cause mortality (ACM) risk. DESIGN, SETTING, AND PARTICIPANTS: The study cohort comprised 639 men with clinical T1-4,N0M0 biopsy Gleason score 9-10 prostate cancer. Between February 6, 1992, and April 26, 2013, a total of 80 men were consecutively treated with MaxRT at the Chicago Prostate Cancer Center, and 559 men were consecutively treated with RP and pelvic lymph node dissection at the Martini-Klinik Prostate Cancer Center. Follow-up started on the day of prostate EBRT or RP and concluded on October 27, 2017. EXPOSURES: Of the 559 men managed with RP and pelvic lymph node dissection, 88 (15.7%) received adjuvant EBRT, 49 (8.8%) received ADT, and 50 (8.9%) received both. MAIN OUTCOMES AND MEASURES: Treatment propensity score-adjusted risk of PCSM and ACM and the likelihood of equivalence of these risks between treatments using a plausibility index. RESULTS: The cohort included 639 men, with a mean (SD) age of 65.83 (6.52) years. After median follow-ups of 5.51 years (interquartile range, 2.19-6.95 years) among 80 men treated with MaxRT and 4.78 years (interquartile range, 4.01-6.05 years) among 559 men treated with RP-containing treatments, 161 men had died, 106 (65.8%) from prostate cancer. There was no significant difference in the risk of PCSM (adjusted hazard ratio, 1.33; 95% CI, 0.49-3.64; P = .58) and ACM (adjusted hazard ratio, 0.80; 95% CI, 0.36-1.81; P = .60) when comparing men who underwent MaxRP vs MaxRT, with plausibility indexes for equivalence of 76.75% for the end point of the risk of PCSM and 77.97% for the end point of the risk of ACM. Plausibility indexes for all other treatment comparisons were less than 63%. CONCLUSIONS AND RELEVANCE: Results of this study suggest that it is plausible that treatment with MaxRP or MaxRT for men with biopsy Gleason score 9-10 prostate cancer can lead to equivalent risk of PCSM and ACM.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Tilki D, Chen MH, Wu J, et al. Surgery vs Radiotherapy in the Management of Biopsy Gleason Score 9-10 Prostate Cancer and the Risk of Mortality. JAMA Oncol. 2019. PMID: 30452521. doi:10.1001/jamaoncol.2018.4836

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。